As of Friday close, CareDx Inc’s (NASDAQ:CDNA) stock was down -$0.06, moving down -0.71 percent to $8.41. The average number of shares traded per day over the past five days has been 749,500 shares. 2 times new highs have been achieved over the past 5 days, with a -$0.49 fall in that time frame. In the last twenty days, the average volume was 912,460, while in the previous 50 days, it was 1,011,432.
Since last month, CDNA stock retreated -16.15%. Shares of the company fell to $8.34 on 08/18/23, the lowest level in the past month. A 52-week high of $22.03 was reached on 02/02/23 after having rallying from a 52-week low of $6.22. Since the beginning of this year, CDNA’s stock price has dropped by -26.29% or -$3.00, and marked a new high 12 times. However, the stock has declined by -61.82% since its 52-week high.
CDNA stock investors should be aware that CareDx Inc (CDNA) stock had its last reported insider trading activity 5 days ago on Aug 14. Seeto Reginald, the of the company, disposed of 576 shares for $8.89 on Aug 14. It resulted in a $5,123 divestment by the insider. Seeto Reginald sold 2,819 shares at an average price of $11.35 on Aug 02. The insider now owns 486,051 shares following the transaction. On Jul 13, Seeto Reginald sold 5,260 shares at $10.33 apiece. The transaction was valued at $54,357.
Valuation Metrics
The stock’s beta is 0.99. Besides these, the trailing price-to-sales (P/S) ratio of 1.59, the price-to-book (PB) ratio of 1.12.
Financial Health
In the three months ended June 29, CareDx Inc’s quick ratio stood at 4.60, while its current ratio was 4.80, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 64.60% percent. In the year ended June 29, EBITDA margin amounted to -19.03%, whereas operating margins totaled -28.60%. Based on annual data, CDNA earned $209.58 million in gross profit and brought in $321.79 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -18.00%. Return on equity (ROE) for the past 12 months was -19.80%.
According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. CDNA’s revenue fell -14.69% to $77.26 million during the quarter, while net income inched up to $70.3 million. While analysts expected CareDx Inc to report -$0.31 quarterly earnings, the actual figure was -$0.18 per share, beating the consensus estimate by 41.90%. During the quarter, the company generated -$23.96 million in EBITDA. The liabilities of CareDx Inc were 109.61 million at the end of its most recent quarter ended June 29, and its total debt was $36.4 million. The value of shareholders’ equity is $54.17 million.
Technical Picture
This quick technical analysis looks at CareDx Inc’s (CDNA) price momentum. With a historical volatility rate of 87.94%, the RSI 9-day stood at 32.35% on 18 August.
With respect to its five-day moving average, the current CareDx Inc price is down by -5.51% percent or -$0.49. At present, CDNA shares trade -20.88% below its 20-day simple moving average and -7.38% percent below its 100-day simple moving average. However, the stock is currently trading approximately +0.24% above its SMA50 and -57.76% below its SMA200.
Stochastic coefficient K was 3.54% and Stochastic coefficient D was 12.83%, while ATR was 0.78. Given the Stochastic reading of 2.02% for the 14-day period, the RSI (14) reading has been calculated as 37.97%. As of today, the MACD Oscillator reading stands at -0.80, while the 14-day reading stands at -1.35.
Analyst Ratings
Raymond James upgraded its rating on CareDx Inc (NASDAQ: CDNA) to an Outperform in a note to investors on August 15, 2023. The analysts firm previously had a Mkt perform rating on the stock.CareDx Inc (CDNA) has been rated Overweight by analysts. According to 0 brokerage firms, CDNA is a sell, and 4 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 1 analyst rate CareDx Inc stock as buy, with 2 recommending it as overweight.
